“Since the assessment of breast cancer risk in patients during drug development is not possible … studies in large populations, this study provides new evidence that a therapeutic dose of estetrol for … progesterone or drospirenone, may provide a better benefit/risk profile … to the hormonal treatments currently available for patients.”